enGene Holdings Inc. WarrantsENGNW
About: enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Employees: 57
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
1.43% less ownership
Funds ownership: 10.77% [Q4 2024] → 9.34% (-1.43%) [Q1 2025]
7% less funds holding
Funds holding: 15 [Q4 2024] → 14 (-1) [Q1 2025]
28% less capital invested
Capital invested by funds: $4.02M [Q4 2024] → $2.91M (-$1.11M) [Q1 2025]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for ENGNW.
Financial journalist opinion
We haven’t received any recent news articles for ENGNW.